Fortrea Holdings (FTRE) Total Current Liabilities (2022 - 2026)
Fortrea Holdings (FTRE) posted Total Current Liabilities of $929.1 million for Q1 2026, up 1.73% on a QoQ basis from $913.3 million in Q4 2025, and down 7.01% year-over-year from $999.1 million in Q1 2025.
Fortrea Holdings (FTRE) Total Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $929.1 million for Q1 2026.
- Quarterly Total Current Liabilities fell 7.01% year-over-year to $929.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $929.1 million (down 7.01% YoY) and the FY2025 annual result came in at $913.3 million, down 3.81% from the prior year.
- Total Current Liabilities was $929.1 million for Q1 2026 at Fortrea Holdings, up from $913.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $999.1 million in Q1 2025 and bottomed at $699.0 million in Q4 2022.
- A 5-year average of $847.3 million and a median of $818.3 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities rose 25.81% — and 2026, when it fell 7.01%.
- Fortrea Holdings' Total Current Liabilities stood at $699.0 million in 2022, then gained by 11.36% to $778.4 million in 2023, then rose by 21.98% to $949.5 million in 2024, then slipped by 3.81% to $913.3 million in 2025, then rose by 1.73% to $929.1 million in 2026.
- Business Quant data shows FTRE's Total Current Liabilities at $929.1 million in Q1 2026, $913.3 million in Q4 2025, and $914.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 929.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 929.10 Mn |
| Dec 31, 2025 | 913.30 Mn |
| Sep 30, 2025 | 914.40 Mn |
| Jun 30, 2025 | 942.30 Mn |
| Mar 31, 2025 | 999.10 Mn |
| Dec 31, 2024 | 949.50 Mn |
| Sep 30, 2024 | 795.80 Mn |
| Jun 30, 2024 | 749.00 Mn |
| Mar 31, 2024 | 818.30 Mn |
| Dec 31, 2023 | 778.40 Mn |
| Sep 30, 2023 | 774.60 Mn |
| Jun 30, 2023 | 752.10 Mn |
| Dec 31, 2022 | 699.00 Mn |